Ortho-Clinical Diagnostics, Inc.

Ortho-Clinical Diagnostics, Inc. manufactures and supplies blood bank analyzers, clinical chemistry systems, diagnostic reagents, and laboratory consumables to the federal government as a prime contractor, competing exclusively in full-and-open procurements without set-aside designations. The company is a self-certified HUBZone joint venture headquartered in Raritan, New Jersey, operating as a subsidiary of parent company Quidelortho Corporation. Ortho-Clinical Diagnostics serves 67 distinct federal agencies across a 5,933-award portfolio spanning nearly five decades, with recent activity dominated by delivery orders and blanket purchase agreement calls for blood bank testing supplies, analyzer maintenance, and laboratory reagents.

The vendor's customer base concentrates heavily on Department of Defense logistics, Department of Veterans Affairs regional networks, and Department of Health and Human Services Indian Health Service operations. By award count, the top five customers account for 71% of recent awards, with Defense Logistics Agency Troop Support Medical placing 2,588 orders (combined potential value $55.1 million), followed by the Department of Justice Bureau of Prisons ($8.1 million), Indian Health Service ($57 million), Department of Navy ($47.7 million), and Department of Army Medical Command ($54.6 million). By potential value, the concentration shifts upward: Veterans Integrated Service Network 9 dominates at $116.2 million across 142 awards, VISN 22 follows at $92 million across 108 awards, and Indian Health Service ranks third at $57 million. The ranking divergence reflects Ortho-Clinical's role as a high-volume, low-unit-cost supplier to DLA logistics operations (high count, modest per-order value) alongside larger equipment and reagent packages to VA regional networks (lower count, higher dollar value per transaction).

Ortho-Clinical's prime vehicle portfolio is anchored to the General Services Administration's Critical Analyzers, Laboratory (FSS-66-III) multiple-award schedule, which carries 2,862 task orders worth $598.5 million in combined potential value. The vendor also maintains two indefinite delivery contracts under the Defense Logistics Agency supply chain: SPE2D018D0005 (1,379 task orders, $1.6 million) and SPE2DE21D0007 (1,206 task orders, $4 million). A separate IDC with the Department of Health and Human Services (HHSI241201300009I) supports Indian Health Service operations with 59 task orders valued at $1.8 million. The vendor holds a five-year $2.1 million Defense Health Agency blood bank testing blanket purchase agreement awarded in April 2026, and a single-award $80 thousand Indian Health Service blanket purchase agreement for the Hopi Health Care Center established in May 2025.

Activity has fluctuated substantially in recent years: 505 awards in 2022, declining to 476 in 2023, recovering to 640 in 2024, then contracting sharply to 389 in 2025 and 15 year-to-date awards in 2026. Twenty-eight awards carrying $11 million in combined potential value will reach ultimate completion within the next twenty-four months, creating recompete exposure. The vendor's capability portfolio spans blood bank automation cost-per-test solutions, dry chemistry immunochemistry systems, blood bank gel analyzers, VITROS chemistry analyzer systems and reagents, blood bank reagent consumables (Anti-A, Anti-B, Anti-D bioclone formulations, Anti-Kell, Anti-E, and other rare blood cell antibodies), quality control sera, and preventive maintenance services. Representative contracts include a $1.75 million Dry Chemistry Immunochemistry System delivery order with Veterans Integrated Service Network 22 (placed April 2026), a $1.34 million dry chemistry immunochemistry system delivery order for VISN 22 (August 2026), a $431 thousand blood bank analyzer reagents and consumables blanket purchase agreement with VISN 10 (September 2026), a $326 thousand Ortho blood bank reagents delivery order with VISN 2 (July 2026), and a $360 thousand VITROS 5600 laboratory reagents and supplies delivery order with Indian Health Service (September 2025).

The vendor operates entirely as a prime contractor (100% of awards) with no subcontractor engagement across its award portfolio. Service Contract Inventory data indicates minimal federal service-contract labor activity: only $4 thousand in SCI-reportable invoiced revenue across FY2022–FY2025, with 0.4 FTEs reported in FY2024 alone. This reflects the vendor's business model as a product manufacturer and goods supplier rather than a services firm; SCI captures the narrow slice of federal contracts above the $150 thousand reporting threshold that involve labor services, excluding the vast majority of Ortho-Clinical's high-volume, low-unit-value transactional orders for reagents and consumables.

The vendor's federal award concentration by product category reflects its specialization in diagnostic laboratory goods: 2,588 awards fall under the NAICS Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers category, 1,963 under In-Vitro Diagnostic Substance Manufacturing, and 1,056 under Analytical Laboratory Instrument Manufacturing. PSC coding mirrors this framing, with 1,603 awards classified under Laboratory Equipment and Supplies, 1,358 under In Vitro Diagnostic Substances, and 1,227 under Drugs and Biologicals. The company competes in full-and-open federal procurements against manufacturers such as Siemens Healthcare Diagnostics, Grifols Inc., and other blood bank and clinical chemistry equipment suppliers, leveraging its GSA Schedule multiple-award vehicle, established relationships with VA and Defense Health Agency contracting officers, and product offering depth in blood bank reagents and analyzer systems to secure repetitive ordering across distributed federal healthcare facilities.